Genzyme Corp. on Wednesday said it has started clinical studiesof a bioresorbable membrane designed to reduce the formationof post-surgical adhesions.

The trials, under an investigational device exemptionapplication, are expected to take two years. SpokeswomanDonna LaVoie said that the product, HAL-F, will be marketed in1995-1996.

HAL-F is one of four products based on hyaluronic acid (HA)that Genzyme is developing. The products are principallyintended to be used by surgeons to reduce the incidence,severity and extent of postoperative adhesions. In addition,they are expected to play a key role in protecting tissues fromtrauma in a variety of surgical procedures.

HAL-F is designed for use following surgery to provide atemporary physical barrier covering severely traumatizedtissues, preventing formation of adhesions between normallyseparated surfaces.

The Cambridge, Mass., company (NASDAQ:GENZ) estimates thepotential U.S. market for HAL-F at $200 million to $300 millionannually, and the market for its HA family of products at $800million.

The first HA product, HAL-S synovial fluid replacement, isexpected to be marketed in 1994, according to the company.The product is expected to reduce incidental damage fromtissue manipulation during arthroscopic procedures.

The stock closed Wednesday at $46.75, down $1.

-- Steve Usdin BioWorld Washington Bureau

(c) 1997 American Health Consultants. All rights reserved.